ACADEMY OF MANAGED CARE PHARMACY for ACADEMY OF MANAGED CARE PHARMACY
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
HR 2112 - appropriations legislation covering the Food and Drug Administration. Also discussed topic of FDA funding generally with Senate staff.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Medicare/Medicaid MMM
HR 891 and S 274 - legislation that would expand the exisiting medication therapy management program in Medicare Part D S 31 and S 34 - legislation that would require or allow the federal government to negotiate prescription drug prices on behalf of Medicare Part D plan sponsors HR 999 and S 560 - legislation that would establish a nationwide Part D plan administered by the federal government HR 2190 and S 1206 - legislation that would require prescription drug manufacturers to pay Medicaid "best price" rebates for covered prescription drugs purchased by dual eligibles under Medicare Part D. This issue, along with federal negotiation of prescription drug prices for Part D plan sponsors, was also addressed in a comment letter sent during negotiations on deficit reduction plans in June 2011 to the White House and members of Congress. Worked on proposed legislative language, work which included consultation with Senate committee staff, that would amend the current prompt payment rules in Medicare Part D in the interest of preventing fraud.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Labor Issues/Antitrust/Workplace LBR
HR 1893 - legislation that would grant an exemption from antitrust laws to certain independent pharmacists and allow them to collectively negotiate contract terms and conditions with health plans and pharmacy benefit managers.
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Pharmacy PHA
S 27 - legislation that would authorize the Federal Trade Commission to presume illegal agreements between manufacturers of innovator and generic pharmaceutical products in which the generic manufacturer agrees to delay entry into the market in exchange for compensation from the manufacturer of the innovator product. HR 1483 - legislation that would introduce reforms and reauthorizations of the FDA, including the prescription drug user fee act
| Lobbyist | Covered position, as disclosed |
|---|---|
| MELISSA ANDEL | — |
| LAUREN LEA FULLER | — |
| WILLIAM HERMELIN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.